No Data
No Data
Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)
Revance Therapeutics Ticks Higher as Holder Says Crown Deal Undervalues Company
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories
No Data